Argenx closed its third quarter of 2026 with a financial statement that seems designed to fuel two very different arguments. On one side, you have the raw numbers of a commercial blockbuster. Vyvgart product sales reached about $1.7 billion for the quarter. Basic earnings per share landed at $8.07. That is not just growth. It is a tidal wave of revenue and profit. The company’s trailing net margin sits at a robust 31.7%, according to their latest earnings report. These are the figures of a company that has successfully launched and scaled a flagship therapy.
Yet the stock price tells a more muted story. Shares closed at €782.2 on October 23, roughly flat for the week and soft over the prior month. This disconnect is where the real analysis begins. The market is no longer simply rewarding top line growth. It is now scrutinizing the cost of ambition. The central question has shifted from whether Vyvgart can sell to whether argenx can build a sustainable platform around it. Investors are pricing in a debate.
The bullish thesis is clear and compelling. It views Vyvgart as merely the first chapter. The acquisition of Forte Biosciences and its drug candidate FB102 is the plot twist. Company leadership has stated this move reframes argenx as a two platform immunology company. Early signs support the narrative. FB102 recently reported positive Phase 2 data in celiac disease, with a Phase 3 trial now on the calendar. Another pipeline asset, empasiprubart, heads toward a critical data readout for MMN in December 2026. This is the blueprint for a major biopharma entity. Revenue diversification de-risks the long term story. It promises a broader earnings base that could support today’s premium valuation.
However, the financials reveal the substantial price tag for this ambition. The bearish case focuses squarely on the cost trajectory. Company guidance points to combined R&D and SG&A expenses hitting roughly $4 billion for full year 2026. That represents an increase of about 45% over 2025. This is not speculative. The Q3 report makes it concrete. The quarter included $150 million in transaction charges related to the Forte acquisition. It also incorporated the first step up in ongoing operational expenses from the deal. The higher cost baseline is now a reality embedded in the income statement.
This spending surge creates a tangible financial risk. The concern is that this enlarged cost structure will grow faster than new product revenue can offset it. If that happens, it would directly cap operating margin expansion. It could dampen the earnings growth that shareholders currently expect. The Q3 operating margin of 28%, or 37% when excluding those Forte related costs, shows Vyvgart’s profitability engine is still powerful. But it also shows the new drag. The margin compression is visible in the year over year comparison. Argenx’s trailing net profit margin has declined from 41.6% to 31.7%. Some of this is the natural cost of integrating an acquisition and funding new trials. Investors must decide how much is structural.
This is the pivotal moment for argenx. The company has proven it can achieve commercial excellence with a single product. The next test is portfolio discipline. Can it advance its new platforms without allowing spending to erode the formidable profits its core asset generates? The 2026 expense guidance provides the first clear answer. The market’s hesitant share price reaction suggests skepticism is warranted. It is a reminder that in biotech, scientific promise and financial execution must advance together. One cannot outrun the other for long.
- Vyvgart product sales reached about $1.7 billion
- Basic earnings per share landed at $8.07
- Trailing net margin sits at 31.7%
- Company guidance points to combined R&D and SG&A expenses of $4 billion
- Q3 operating margin of 28%
- Trailing net profit margin has declined from 41.6% to 31.7%
| Metric | Q3 2026 | Previous Year |
|---|---|---|
| Product Sales | $1.7 billion | $1.1 billion |
| Basic Earnings per Share | $8.07 | $5.00 |
| Trailing Net Margin | 31.7% | 41.6% |
| Operating Margin | 28% | 27% |
| Combined R&D and SG&A Expenses | $4 billion | $2.76 billion |
| FB102 Phase 2 Data | Positive | N/A |
